Inhibition of casein kinase II reduces TGFβ induced fibroblast activation and ameliorates experimental fibrosis

Objectives Casein kinase II (CK2) is a constitutively active serine/threonine protein kinase that plays a key role in cellular transformation and tumorigenesis. The purpose of the study was to characterise whether CK2 contributes to the pathologic activation of fibroblasts in patients with SSc and to evaluate the antifibrotic potential of CK2 inhibition. Methods Activation of CK2, JAK2 and STAT3 in human skin and in experimental fibrosis was analysed by immunohistochemistry. CK2 signalling was inhibited by the selective CK2 inhibitor 4, 5, 6, 7-Tetrabromobenzotriazole (TBB). The mouse models of bleomycin-induced and TGFβ receptor I (TBR)-induced dermal fibrosis were used to evaluate the antifibrotic potential of specific CK2 inhibition in vivo. Result Increased expression of CK2 was detected in skin fibroblasts of SSc patients. Inhibition of CK2 by TBB abrogated the TGFβ-induced activation of JAK2/STAT3 signalling and prevented the stimulatory effects of TGFβ on collagen release and myofibroblasts differentiation in cultured fibroblasts. Inhibition of CK2 prevented bleomycin-induced and TBR-induced skin fibrosis with decreased dermal thickening, lower myofibroblast counts and reduced accumulation of collagen. Treatment with TBB also induced regression of pre-established fibrosis. The antifibrotic effects of TBB were accompanied by reduced activation of JAK2/STAT3 signalling in vivo. Conclusions We provide evidence that CK2 is activated in SSc and contributes to fibroblast activation by regulating JAK2/STAT3 signalling. Inhibition of CK2 reduced the pro-fibrotic effects of TGFβ and inhibited experimental fibrosis. Targeting of CK2 may thus be a novel therapeutic approach for SSc and other fibrotic diseases.

[1]  M. Haslbeck,et al.  THU0060 Clinical Phenotypes of Systemic Sclerosis Impact Telomere and Telosome Function in Distinct Patterns , 2013 .

[2]  G. Schett,et al.  The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis , 2013, Annals of the rheumatic diseases.

[3]  G. Schett,et al.  Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-β signalling to prevent fibrosis , 2013, Annals of the rheumatic diseases.

[4]  J. Varga,et al.  Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis , 2013, Annals of the rheumatic diseases.

[5]  S. Moro,et al.  Kinase CK2 inhibition: an update. , 2013, Current medicinal chemistry.

[6]  G. Schett,et al.  Activation of pregnane X receptor inhibits experimental dermal fibrosis , 2013, Annals of the rheumatic diseases.

[7]  G. Schett,et al.  Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling , 2012, Annals of the rheumatic diseases.

[8]  J. Zwerina,et al.  JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor β in systemic sclerosis. , 2012, Arthritis and rheumatism.

[9]  B. Cravatt,et al.  Inactivation of fatty acid amide hydrolase exacerbates experimental fibrosis by enhanced endocannabinoid-mediated activation of CB1 , 2012, Annals of the rheumatic diseases.

[10]  G. Schett,et al.  Inhibition of H3K27 histone trimethylation activates fibroblasts and induces fibrosis , 2012, Annals of the rheumatic diseases.

[11]  Veronika Lang,et al.  Inhibition of sumoylation prevents experimental fibrosis , 2012, Annals of the rheumatic diseases.

[12]  G. Schett,et al.  Pomalidomide is effective for prevention and treatment of experimental skin fibrosis , 2012, Annals of the rheumatic diseases.

[13]  Oliver Distler,et al.  Inhibition of activator protein 1 signaling abrogates transforming growth factor β-mediated activation of fibroblasts and prevents experimental fibrosis. , 2012, Arthritis and rheumatism.

[14]  B. de Crombrugghe,et al.  β-catenin is a central mediator of pro-fibrotic Wnt signaling in systemic sclerosis , 2012, Annals of the Rheumatic Diseases.

[15]  G. Schett,et al.  Stimulation of soluble guanylate cyclase reduces experimental dermal fibrosis , 2012, Annals of the rheumatic diseases.

[16]  Oliver Distler,et al.  Activation of canonical Wnt signalling is required for TGF-β-mediated fibrosis , 2012, Nature Communications.

[17]  A. Tefferi,et al.  A CK2-dependent mechanism for activation of the JAK-STAT signaling pathway. , 2011, Blood.

[18]  N. Alenina,et al.  Platelet-derived serotonin links vascular disease and tissue fibrosis , 2011, The Journal of experimental medicine.

[19]  M. Mattson,et al.  Inhibition of Notch signaling prevents experimental fibrosis and induces regression of established fibrosis. , 2011, Arthritis and rheumatism.

[20]  M. Yaniv,et al.  The transcription factor JunD mediates transforming growth factor β-induced fibroblast activation and fibrosis in systemic sclerosis , 2011, Annals of the rheumatic diseases.

[21]  Oliver Distler,et al.  Notch signalling regulates fibroblast activation and collagen release in systemic sclerosis , 2011, Annals of the rheumatic diseases.

[22]  G. Schett,et al.  Inactivation of the transcription factor STAT-4 prevents inflammation-driven fibrosis in animal models of systemic sclerosis. , 2011, Arthritis & Rheumatism.

[23]  Adam Siddiqui-Jain,et al.  CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. , 2010, Cancer research.

[24]  M. Montenarh.  Cellular regulators of protein kinase CK2 , 2010, Cell and Tissue Research.

[25]  G. Schett,et al.  Animal models of systemic sclerosis: prospects and limitations. , 2010, Arthritis & Rheumatism.

[26]  E. Feierl,et al.  Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database , 2010, Annals of the rheumatic diseases.

[27]  C. Van Waes,et al.  CK2 Modulation of NF-κB, TP53, and the Malignant Phenotype in Head and Neck Cancer by Anti-CK2 Oligonucleotides In vitro or In vivo via Sub–50-nm Nanocapsules , 2010, Clinical Cancer Research.

[28]  Oliver Distler,et al.  Rho-associated kinases are crucial for myofibroblast differentiation and production of extracellular matrix in scleroderma fibroblasts. , 2008, Arthritis and rheumatism.

[29]  L. Pinna,et al.  A structural insight into CK2 inhibition , 2008, Molecular and Cellular Biochemistry.

[30]  D. Pisetsky,et al.  The induction of matrix metalloproteinase and cytokine expression in synovial fibroblasts stimulated with immune cell microparticles. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Isabel Dominguez,et al.  CK2 Phosphorylation of the Armadillo Repeat Region of β-Catenin Potentiates Wnt Signaling* , 2003, Journal of Biological Chemistry.

[32]  T. Medsger,et al.  Criteria for the classification of early systemic sclerosis. , 2001, The Journal of rheumatology.

[33]  R. Cardiff,et al.  Protein kinase CK2 in mammary gland tumorigenesis , 2001, Oncogene.

[34]  K. Ahmed,et al.  Elevated protein kinase CK2 activity in chromatin of head and neck tumors: association with malignant transformation. , 1996, Cancer letters.

[35]  O. Issinger,et al.  Asymmetric expression of protein kinase CK2 subunits in human kidney tumors. , 1994, Biochemical and biophysical research communications.

[36]  J. Hogg,et al.  Activation of a tumor-associated protein kinase (p40TAK) and casein kinase 2 in human squamous cell carcinomas and adenocarcinomas of the lung. , 1994, Cancer research.

[37]  S. Goueli,et al.  Nuclear casein kinase 2 (CK‐2) activity in human normal, benign hyperplastic, and cancerous prostate , 1994, The Prostate.

[38]  R. Samarakoon,et al.  TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities. , 2013, Cellular signalling.

[39]  S. Gay,et al.  The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis. , 2010, Arthritis and rheumatism.

[40]  Oliver Distler,et al.  Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. , 2009, Arthritis and rheumatism.

[41]  James S. Duncan,et al.  Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. , 2008, Biochimica et biophysica acta.

[42]  D. Litchfield.  Protein kinase CK2: structure, regulation and role in cellular decisions of life and death. , 2003, The Biochemical journal.